These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30689946)

  • 21. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties.
    Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M
    Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.
    Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M
    J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
    Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
    Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors.
    Oramas-Royo S; Haidar S; Amesty Á; Martín-Acosta P; Feresin G; Tapia A; Aichele D; Jose J; Estévez-Braun A
    Bioorg Chem; 2020 Jan; 95():103520. PubMed ID: 31887475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumoral activity of allosteric inhibitors of protein kinase CK2.
    Moucadel V; Prudent R; Sautel CF; Teillet F; Barette C; Lafanechere L; Receveur-Brechot V; Cochet C
    Oncotarget; 2011 Dec; 2(12):997-1010. PubMed ID: 22184283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
    Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
    Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
    Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
    Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
    Schnitzler A; Niefind K
    Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
    Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
    Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.
    Guerra B; Hochscherf J; Jensen NB; Issinger OG
    Mol Cell Biochem; 2015 Aug; 406(1-2):151-61. PubMed ID: 25963666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting.
    Greco FA; Krämer A; Wahl L; Elson L; Ehret TAL; Gerninghaus J; Möckel J; Müller S; Hanke T; Knapp S
    Eur J Med Chem; 2024 Oct; 276():116672. PubMed ID: 39067440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.
    Laudet B; Barette C; Dulery V; Renaudet O; Dumy P; Metz A; Prudent R; Deshiere A; Dideberg O; Filhol O; Cochet C
    Biochem J; 2007 Dec; 408(3):363-73. PubMed ID: 17714077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
    Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
    Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin.
    Cozza G; Zonta F; Dalle Vedove A; Venerando A; Dall'Acqua S; Battistutta R; Ruzzene M; Lolli G
    FEBS J; 2020 May; 287(9):1850-1864. PubMed ID: 31661600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors.
    Chekanov MO; Ostrynska OV; Synyugin AR; Bdzhola VG; Yarmoluk SM
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):338-43. PubMed ID: 23578312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
    Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
    Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.